Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | v-ets avian erythroblastosis virus E26 oncogene homolog | Starlite/ChEMBL | No references |
Human immunodeficiency virus 1 | Aberrant vpr protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | ko:K09435 transcriptional regulator ERG, putative | Get druggable targets OG5_131947 | All targets in OG5_131947 |
Brugia malayi | Fli-1 protein | Get druggable targets OG5_131947 | All targets in OG5_131947 |
Loa Loa (eye worm) | fli-1 protein | Get druggable targets OG5_131947 | All targets in OG5_131947 |
Schistosoma mansoni | ets-related | Get druggable targets OG5_131947 | All targets in OG5_131947 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hexokinase | 0.1032 | 1 | 1 |
Plasmodium falciparum | hexokinase | 0.1032 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.1032 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0704 | 0.5396 | 0.5396 |
Trypanosoma brucei | hexokinase | 0.1032 | 1 | 0.5 |
Onchocerca volvulus | 0.1032 | 1 | 1 | |
Echinococcus multilocularis | hexokinase | 0.1032 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0647 | 0.4604 | 0.4604 |
Onchocerca volvulus | 0.1032 | 1 | 1 | |
Toxoplasma gondii | hexokinase | 0.1032 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.1032 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.1032 | 1 | 1 |
Brugia malayi | hexokinase type II | 0.0328 | 0.0123 | 0.0123 |
Echinococcus multilocularis | hexokinase | 0.1032 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.1032 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.1032 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.1032 | 1 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.1032 | 1 | 0.5 |
Onchocerca volvulus | 0.1032 | 1 | 1 | |
Trypanosoma cruzi | hexokinase, putative | 0.1032 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.1032 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.0647 | 0.4604 | 0.4604 |
Trypanosoma brucei | hexokinase, putative | 0.1032 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.1032 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.1032 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0328 | 0.0123 | 0.0123 |
Leishmania major | hexokinase, putative | 0.1032 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.1032 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.1032 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0328 | 0.0123 | 0.0123 |
Leishmania major | hexokinase, putative | 0.1032 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.1032 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.1032 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.1032 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.1032 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.8913 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488939] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.